Company intelligence / Profile preview

Samaritans

Ownership: Private
Employees: ~8
Development stage: Other

Overview

Samaritan Pharmaceuticals was a biopharmaceutical company focused on developing innovative therapeutics for CNS disorders and cancer. It advanced three drugs into human clinical trials by 2007 and in-licensed multiple specialty products for commercialization in Europe. The company is no longer active as of the latest available information from BioCentury.

Therapeutic areas: OncologyNeurologyOther
Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

Abiogen—commercialization rights for Abioklad cancer drug in Greece, Cyprus, TurkeyEUSA—exclusive license to commercialize ERWINASE and KIDROLASE oncology drugs in Greece and Cyprus

Beyond the preview

Go deeper on Samaritans.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Samaritans.

Explore the full profile